Compare WHR & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHR | INDV |
|---|---|---|
| Founded | 1911 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 1994 | 2014 |
| Metric | WHR | INDV |
|---|---|---|
| Price | $56.16 | $37.62 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $74.33 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 05-06-2026 | 06-08-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | 196.42 | ★ 8100.00 |
| EPS | ★ 5.66 | 1.64 |
| Revenue | ★ $21,253,000,000.00 | $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.48 | N/A |
| P/E Ratio | ★ $9.67 | $20.91 |
| Revenue Growth | 2.58 | ★ 4.29 |
| 52 Week Low | $50.41 | $10.91 |
| 52 Week High | $111.96 | $38.00 |
| Indicator | WHR | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 72.08 |
| Support Level | $50.41 | $32.43 |
| Resistance Level | $58.69 | $37.83 |
| Average True Range (ATR) | 2.37 | 1.41 |
| MACD | 0.37 | 0.46 |
| Stochastic Oscillator | 56.13 | 79.34 |
Whirlpool Corp is a manufacturer and marketer of kitchen and laundry appliances, with its presence in different markets around the world. It offers products like refrigerators, washing machines, cooktops, ovens, freezers, and others, which are marketed through various brands such as KitchenAid, Maytag, Amana, Brastemp, Consul, Whirlpool, Jennair, etc. The company's operating and reportable segments are: Major Domestic Appliances (MDA) North America (its key revenue-generating segment), MDA Europe, MDA Latin America, and Small Domestic Appliances (SDA) Global.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).